Research ExplorerPublicationsThe use of PET/CT in prostate cancer

The use of PET/CT in prostate cancer

Standard

The use of PET/CT in prostate cancer. / Li, R.; Ravizzini, G. C.; Gorin, M. A.; Maurer, T.; Eiber, M.; Cooperberg, M. R.; Alemozzaffar, M.; Tollefson, M. K.; Delacroix, S. E.; Chapin, B. F.

In: PROSTATE CANCER P D, Vol. 21, No. 1, 04.2018, p. 4-21.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Li, R, Ravizzini, GC, Gorin, MA, Maurer, T, Eiber, M, Cooperberg, MR, Alemozzaffar, M, Tollefson, MK, Delacroix, SE & Chapin, BF 2018, 'The use of PET/CT in prostate cancer', PROSTATE CANCER P D, vol. 21, no. 1, pp. 4-21. https://doi.org/10.1038/s41391-017-0007-8

APA

Li, R., Ravizzini, G. C., Gorin, M. A., Maurer, T., Eiber, M., Cooperberg, M. R., Alemozzaffar, M., Tollefson, M. K., Delacroix, S. E., & Chapin, B. F. (2018). The use of PET/CT in prostate cancer. PROSTATE CANCER P D, 21(1), 4-21. https://doi.org/10.1038/s41391-017-0007-8

Vancouver

Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR et al. The use of PET/CT in prostate cancer. PROSTATE CANCER P D. 2018 Apr;21(1):4-21. https://doi.org/10.1038/s41391-017-0007-8

Bibtex

@article{f970b9d0b9934e0c9cabb45774afd93e,
title = "The use of PET/CT in prostate cancer",
abstract = "BACKGROUND: Positron emission tomography/computed tomography (PET/CT) has recently emerged as a promising diagnostic imaging platform for prostate cancer. Several radiolabelled tracers have demonstrated efficacy for cancer detection in various clinical settings. In this review, we aim to illustrate the diverse use of PET/CT with different tracers for the detection of prostate cancer. METHODS: We searched MEDLINE using the terms 'prostate cancer', 'PET', 'PET/CT' and 'PET/MR'). The current review was limited to (18)F-NaF PET/CT, choline-based PET/CT, fluciclovine PET/CT and PSMA-targeted PET/CT, as these modalities have been the most widely adopted. RESULTS: NaF PET/CT has shown efficacy in detecting bone metastases with high sensitivity, but relatively low specificity. Currently, choline PET/CT has been the most extensively studied modality. Although having superior specificity, choline PET/CT suffers from low sensitivity, especially at low PSA levels. Nevertheless, choline PET/CT was found to significantly improve upon conventional imaging modalities (CIM) in the detection of metastatic lesions at biochemical recurrence (BCR). Newer methods using fluciclovine and PSMA-targeted radiotracers have preliminarily demonstrated great promise in primary and recurrent staging of prostate cancer. However, their superior efficacy awaits confirmation in larger series. CONCLUSIONS: PET/CT has emerged as a promising staging modality for both primary and recurrent prostate cancer. Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation. Efforts should be aimed at defining their natural history as well as responsiveness and impact of metastasis-directed therapy.",
keywords = "Carboxylic Acids/therapeutic use Choline/therapeutic use Cyclobutanes/therapeutic use Humans Male Multimodal Imaging/trends Neoplasm Recurrence, Local/*diagnostic imaging/pathology Positron Emission Tomography Computed Tomography/*trends Prostate-Specific Antigen/blood Prostatic Neoplasms/blood/*diagnostic imaging/pathology Radioactive Tracers",
author = "R. Li and Ravizzini, {G. C.} and Gorin, {M. A.} and T. Maurer and M. Eiber and Cooperberg, {M. R.} and M. Alemozzaffar and Tollefson, {M. K.} and Delacroix, {S. E.} and Chapin, {B. F.}",
note = "1476-5608 Li, Roger Ravizzini, Gregory C Gorin, Michael A Maurer, Tobias Eiber, Matthias Cooperberg, Matthew R Alemozzaffar, Mehrdad Tollefson, Matthew K Delacroix, Scott E Chapin, Brian F Journal Article Review England Prostate Cancer Prostatic Dis. 2018 Apr;21(1):4-21. doi: 10.1038/s41391-017-0007-8. Epub 2017 Dec 11.",
year = "2018",
month = apr,
doi = "10.1038/s41391-017-0007-8",
language = "English",
volume = "21",
pages = "4--21",
journal = "PROSTATE CANCER P D",
issn = "1365-7852",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - The use of PET/CT in prostate cancer

AU - Li, R.

AU - Ravizzini, G. C.

AU - Gorin, M. A.

AU - Maurer, T.

AU - Eiber, M.

AU - Cooperberg, M. R.

AU - Alemozzaffar, M.

AU - Tollefson, M. K.

AU - Delacroix, S. E.

AU - Chapin, B. F.

N1 - 1476-5608 Li, Roger Ravizzini, Gregory C Gorin, Michael A Maurer, Tobias Eiber, Matthias Cooperberg, Matthew R Alemozzaffar, Mehrdad Tollefson, Matthew K Delacroix, Scott E Chapin, Brian F Journal Article Review England Prostate Cancer Prostatic Dis. 2018 Apr;21(1):4-21. doi: 10.1038/s41391-017-0007-8. Epub 2017 Dec 11.

PY - 2018/4

Y1 - 2018/4

N2 - BACKGROUND: Positron emission tomography/computed tomography (PET/CT) has recently emerged as a promising diagnostic imaging platform for prostate cancer. Several radiolabelled tracers have demonstrated efficacy for cancer detection in various clinical settings. In this review, we aim to illustrate the diverse use of PET/CT with different tracers for the detection of prostate cancer. METHODS: We searched MEDLINE using the terms 'prostate cancer', 'PET', 'PET/CT' and 'PET/MR'). The current review was limited to (18)F-NaF PET/CT, choline-based PET/CT, fluciclovine PET/CT and PSMA-targeted PET/CT, as these modalities have been the most widely adopted. RESULTS: NaF PET/CT has shown efficacy in detecting bone metastases with high sensitivity, but relatively low specificity. Currently, choline PET/CT has been the most extensively studied modality. Although having superior specificity, choline PET/CT suffers from low sensitivity, especially at low PSA levels. Nevertheless, choline PET/CT was found to significantly improve upon conventional imaging modalities (CIM) in the detection of metastatic lesions at biochemical recurrence (BCR). Newer methods using fluciclovine and PSMA-targeted radiotracers have preliminarily demonstrated great promise in primary and recurrent staging of prostate cancer. However, their superior efficacy awaits confirmation in larger series. CONCLUSIONS: PET/CT has emerged as a promising staging modality for both primary and recurrent prostate cancer. Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation. Efforts should be aimed at defining their natural history as well as responsiveness and impact of metastasis-directed therapy.

AB - BACKGROUND: Positron emission tomography/computed tomography (PET/CT) has recently emerged as a promising diagnostic imaging platform for prostate cancer. Several radiolabelled tracers have demonstrated efficacy for cancer detection in various clinical settings. In this review, we aim to illustrate the diverse use of PET/CT with different tracers for the detection of prostate cancer. METHODS: We searched MEDLINE using the terms 'prostate cancer', 'PET', 'PET/CT' and 'PET/MR'). The current review was limited to (18)F-NaF PET/CT, choline-based PET/CT, fluciclovine PET/CT and PSMA-targeted PET/CT, as these modalities have been the most widely adopted. RESULTS: NaF PET/CT has shown efficacy in detecting bone metastases with high sensitivity, but relatively low specificity. Currently, choline PET/CT has been the most extensively studied modality. Although having superior specificity, choline PET/CT suffers from low sensitivity, especially at low PSA levels. Nevertheless, choline PET/CT was found to significantly improve upon conventional imaging modalities (CIM) in the detection of metastatic lesions at biochemical recurrence (BCR). Newer methods using fluciclovine and PSMA-targeted radiotracers have preliminarily demonstrated great promise in primary and recurrent staging of prostate cancer. However, their superior efficacy awaits confirmation in larger series. CONCLUSIONS: PET/CT has emerged as a promising staging modality for both primary and recurrent prostate cancer. Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation. Efforts should be aimed at defining their natural history as well as responsiveness and impact of metastasis-directed therapy.

KW - Carboxylic Acids/therapeutic use Choline/therapeutic use Cyclobutanes/therapeutic use Humans Male Multimodal Imaging/trends Neoplasm Recurrence, Local/diagnostic imaging/pathology Positron Emission Tomography Computed Tomography/trends Prostate-Specific A

U2 - 10.1038/s41391-017-0007-8

DO - 10.1038/s41391-017-0007-8

M3 - SCORING: Review article

C2 - 29230009

VL - 21

SP - 4

EP - 21

JO - PROSTATE CANCER P D

JF - PROSTATE CANCER P D

SN - 1365-7852

IS - 1

ER -